Middle East Conflict & Lyme Vaccine: Pharma Supply Chains & New Hope

March 23, 2026 Dr. Michael Lee – Health Editor Health

The potential for disruption to global pharmaceutical supply chains from the escalating conflict in the Middle East remains limited for now, though manufacturers are bracing for potential increases in transportation costs, according to reporting from STAT News. Whereas the immediate region accounts for a tiny fraction of global pharmaceutical production – 0.3% of medicines and 0.6% of active pharmaceutical ingredients, according to the U.S. Pharmacopeia – the war is already impacting key shipping and air routes.

Manufacturers, particularly those in India and the European Union, may necessitate to seek alternative transportation routes due to potential closures in the Strait of Hormuz, STAT reported. This shift is expected to drive up expenses, which could ultimately be passed on to consumers.

In separate news, Pfizer and Valneva are preparing to approach regulators for approval of a Lyme disease vaccine, despite initial trial results falling short of a key statistical benchmark. The vaccine demonstrated a reduction in Lyme disease risk exceeding 70%, according to STAT. Lyme disease affects an estimated 476,000 people annually in the U.S. And 132,000 in Europe.

The development of a Lyme disease vaccine has been a priority for U.S. Health and Human Services Secretary Robert F. Kennedy Jr., STAT noted. Though, the methodological concerns surrounding the trial could lead to debate within the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention, which are responsible for vaccine recommendations. The Lyme vaccine is one of the few new vaccines anticipated to be reviewed by both agencies in the near future.

Recent reports also indicate the FDA is loosening rules regarding biosimilar approvals, and there has been a noted lack of advisory committee meetings convened by the agency, according to Pharmalot, a STAT News publication. STAT reported on developments regarding pharma lobbying efforts and a new FDA pathway for gene-editing technologies.

,